comscoreMetabolite Markers -- Heard in the Halls: Voices From the 2019 American Society of Clinical Oncology Annual Meeting

Metabolite Markers -- Heard in the Halls: Voices From the 2019 American Society of Clinical Oncology Annual Meeting

Dr. Liz O'Day talks about a test her company is developing that uses metabolites in blood to assess whether a person with metastatic breast cancer will respond to CDK4/6 inhibitors.
Jun 5, 2019
00:00
Download
00:00

Dr. Liz O'Day talks about a test her company is developing that uses metabolites in blood to assess whether a person with metastatic breast cancer will respond to CDK4/6 inhibitors.

About the guest
 
Liz Oday headshot
Elizabeth O'Day, PhD

Dr. Liz O'Day is CEO and founder of Olaris Therapeutics.

— Last updated on May 5, 2022, 6:35 PM

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate